Developed by researchers at the University of Turku in Finland, an immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumours in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.
A new Purdue University technique to analyze proteins expressed on cancer cells shows promise in more rapidly detecting these cell types in patients.
Melanoma tumors that have spread to the brain are equipped to thwart immunotherapies and targeted therapies that succeed against tumors growing in other sites. Researchers at the University of Texas MD Anderson Cancer Center report in Cancer Discovery that the heavy reliance of these tumors on a specific metabolic pathway presents a potentially new therapeutic against these lethal tumors.
Cancer patients who undergo chemotherapy could soon benefit from a new AI that is able to identify and predict the development of different combinations of symptoms -- helping to alleviate much of the distress caused by their occurrence and severity.
The first clinical study investigating the use of the direct oral anticoagulant, rivaroxaban, to prevent blood clots in patients with cancer at high-risk published today in the New England Journal of Medicine. The study found no significant reduction in venous thromboembolism or death in the overall 180-day trial period; however, the researchers did observe a lower incidence of these events while patients were actively on the study drug, or during the on-treatment period.
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.
A new report says without a national investment and commitment to transforming health care delivery in the United States, many people will not benefit from the substantial progress made against cancer.
Treatment with the experimental drug sazituzumab govitecan produced a significant treatment response in patients with difficult-to-treat metastatic triple-negative breast cancer.
A clinical trial at NewYork-Presbyterian/Columbia and other centers found that patients responded to a new 'smart drug' for women with an aggressive form of breast cancer.
Infections with a Human Papillomavirus (HPV) cause 99 percent of cervical cancer cases, and the disease's first sign is often the appearance of precancerous lesions on a woman's cervix. But bacteria may play an important role, too. New research suggests that the cervical microbiome may influence HPV infection more than researchers previously thought.